Background: The latest Paradigm 722 insulin pump, Medtronic MiniMed, USA, enables daily reading of 288 interstitial fluid glucose concentrations determined by a sensor inserted into subcutaneous tissue; the sensor signals are transmitted into the insulin pump, enabling the patient to see real-time glucose concentration on the display and adapt further treatment.
Aims: To assess the evolution of HbA1c over the course of a 3-month period in two cohorts of persons with type 1 (n=39) or type 2 (n=3) diabetes (PWD): 1) PWD on Paradigm 722 using sensors for continuous glucose monitoring (CGM group), 2) PWD on other types of insulin pumps performing intensive self-monitoring as before (3 to 6 times/d) on glucometer Linus, Wellion, Agamatrix (control group).
Methods: Compliant PWDs using insulin pump with insulin aspart for several previous months were included in the study. Seventeen were put on Paradigm 722 with CGM and 25 were included in the control group. Paired t-test and the statistical program SPSS v.15.0 were used to analyze the data.
Results: There was no significant difference in age between the two groups (P=0.996), in diabetes duration (P=0.482) or in daily insulin dose (P=0.469). In the CGM group (but not in the control group) HbA1c/IFCC dropped from 6.98+/-0.43 % to 5.98+/-0.36 % (P=0.006) within 1 month and remained reduced.
Conclusion: The use of the Paradigm 722 insulin pump with CGM resulted in significant improvement in HbA1c which appeared within one month and remained throughout the whole 3-month study period. No significant improvement in HbA1c was seen in the control group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5507/bp.2009.008 | DOI Listing |
Nat Commun
January 2025
Laboratory of Environment-Enhancing Energy (E2E), College of Water Resources and Civil Engineering, China Agricultural University, Beijing, 100083, China.
Biocrude derived from biomass via hydrothermal liquefaction (HTL) is a sustainable substitute for petroleum to obtain energy and biochemicals. Upgrading biocrude inevitably faces the trade-off between consuming large amounts of hydrogen via hydrotreating and high yield of solid residue without additional hydrogen. In this work, we report a non-hydrogenated refinery paradigm for nearly complete valorization (~90%), via co-generating green coal and bio-lubricant.
View Article and Find Full Text PDFAcad Radiol
June 2024
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.C., Y.M., N.R., H.S., R.K., J.S., B.R.M.).
Rationale And Objectives: Fibroblast Activation Protein (FAP) expressing cancer-associated fibroblasts has been a major breakthrough causing a paradigm shift in targeted theranostics focusing on the tumor microenvironment. In this study, a squaric acid derivative DOTA.SA.
View Article and Find Full Text PDFMed Phys
May 2024
Medical Physics Graduate Program, Duke University, Durham, North Carolina, USA.
Background: Delta radiomics is a high-throughput computational technique used to describe quantitative changes in serial, time-series imaging by considering the relative change in radiomic features of images extracted at two distinct time points. Recent work has demonstrated a lack of prognostic signal of radiomic features extracted using this technique. We hypothesize that this lack of signal is due to the fundamental assumptions made when extracting features via delta radiomics, and that other methods should be investigated.
View Article and Find Full Text PDFGut
April 2023
Université Côte d'azur, CNRS, Inserm, iBV, Nice, France
Objective: Intercellular communication within pancreatic ductal adenocarcinoma (PDAC) dramatically contributes to metastatic processes. The underlying mechanisms are poorly understood, resulting in a lack of targeted therapy to counteract stromal-induced cancer cell aggressiveness. Here, we investigated whether ion channels, which remain understudied in cancer biology, contribute to intercellular communication in PDAC.
View Article and Find Full Text PDFJ Med Genet
July 2023
Department of Human Genetics, Emory University, Atlanta, Georgia, USA.
Background: Fabry disease is a rare, multisystemic disorder caused by gene variants that lead to alpha galactosidase A deficiency, resulting in accumulation of glycosphingolipids and cellular dysfunction. Fabry-associated clinical events (FACEs) cause significant morbidity and mortality, yet the long-term effect of Fabry therapies on FACE incidence remains unclear.
Methods: This analysis evaluated incidence of FACEs (as a composite outcome and separately for renal, cardiac and cerebrovascular events) in 97 enzyme replacement therapy (ERT)-naïve and ERT-experienced adults with Fabry disease and amenable variants who were treated with migalastat for up to 8.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!